SSP-004184AQ 100 mg ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 284 | ダイアモンド・ブラックファン貧血 | 1 |
284. ダイアモンド・ブラックファン貧血
臨床試験数 : 37 / 薬物数 : 110 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-006322-25-GB (EUCTR) | 08/10/2012 | 14/08/2012 | Extending the treatment of Iron Overload | A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602). | Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemia; aquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. MedDRA version: 16.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: SSP-004184AQ 50 mg Capsule Product Code: SSP-004184AQ 50 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 100 mg Capsule Product Code: SSP-004184AQ 100 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 200 mg Capsule Product Code: SSP-004184AQ 200 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 250 mg Capsule Product Code: SSP-004184AQ 250 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide Product Name: SSP-004184AQ 375 mg Capsule Product Code: SSP-004184AQ 375 mg INN or Proposed INN: deferitazole Other descriptive name: (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | Shire Development LLC | NULL | Not Recruiting | Female: yes Male: yes | 1500 | Phase 2 | Egypt;United States;Canada;Thailand;Lebanon;Turkey;Italy;United Kingdom |